Holen Sie sich die Stockscreener-App
3.23
2.22%
0.07
Handel nachbörslich:
3.20
-0.03
-0.93%
Schlusskurs vom Vortag:
$3.16
Offen:
$3.24
24-Stunden-Volumen:
3.50M
Relative Volume:
1.42
Marktkapitalisierung:
$583.39M
Einnahmen:
$4.63M
Nettoeinkommen (Verlust:
$-201.14M
KGV:
-2.3506
EPS:
-1.3741
Netto-Cashflow:
$-167.10M
1W Leistung:
+14.54%
1M Leistung:
+14.95%
6M Leistung:
-10.28%
1J Leistung:
+79.44%
1-Tages-Spanne:
$3.10
$3.37
1-Wochen-Bereich:
$2.76
$3.37
52-Wochen-Spanne:
$1.77
$6.94
Prime Medicine Inc Stock (PRME) Company Profile
Firmenname
Prime Medicine Inc
Sektor
Branche
Telefon
617-465-0013
Adresse
60 FIRST ST., CAMBRIDGE
Compare PRME vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
3.23 | 583.39M | 4.63M | -201.14M | -167.10M | -1.3741 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-27 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-05-20 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2025-05-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-12-10 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-20 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-04-22 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-04-08 | Eingeleitet | TD Cowen | Buy |
| 2024-04-03 | Eingeleitet | Wedbush | Outperform |
| 2024-01-16 | Herabstufung | Stifel | Buy → Hold |
| 2023-12-08 | Eingeleitet | Citigroup | Neutral |
| 2023-10-09 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-07-31 | Eingeleitet | Guggenheim | Buy |
| 2023-04-18 | Eingeleitet | Stifel | Buy |
| 2022-11-14 | Eingeleitet | Goldman | Neutral |
| 2022-11-14 | Eingeleitet | JP Morgan | Overweight |
| 2022-11-14 | Eingeleitet | Jefferies | Buy |
| 2022-11-14 | Eingeleitet | Morgan Stanley | Equal-Weight |
Alle ansehen
Prime Medicine Inc Aktie (PRME) Neueste Nachrichten
Prime Medicine’s PM-577a cleared for clinic for Wilson’s disease - BioWorld News
Prime Medicine receives clearance for first in vivo gene therapy trial - Investing.com Canada
Prime Medicine clears first in vivo gene-editing trial for Wilson disease - Stock Titan
Prime Medicine Inc (PRME) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Prime Medicine Inc (PRME) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocular Therapeutix vs Prime Medicine: Two Paths in Medical Innovation - HarianBasis.co
Prime Medicine Inc (PRME) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Prime Medicine Inc (PRME) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Prime Medicine Inc (PRME) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Prime Medicine Inc (PRME) Institutional Confidence - TradingKey
Prime Medicine Inc (PRME) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Prime Medicine Inc (PRME) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Prime Medicine Inc (PRME) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocular Therapeutix vs. Prime Medicine: A 2026 Analysis of Medical Innovation StocksNews and Statistics - IndexBox
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
PRME Q1 2026 Earnings: EPS Misses Estimates Amid Ongoing Development ProgramsEPS Guidance Update - newsline.com
Prime Medicine's Prime Editing Is Worth The Risk (NASDAQ:PRME) - Seeking Alpha
Prime Drink Group announces private placement up to C$2.2M By Investing.com - Investing.com Australia
Prime Drink Group announces private placement up to C$2.2M - Investing.com UK
Prime Medicine (PRME) Holds Steady Near Support as Gene Editing Stock Seeks DirectionBlue Chip Entry Points - newsline.com
PRME Price Today: Prime Medicine, Inc. Stock Price, Quote & Chart | MEXC - MEXC
Transcript : Prime Medicine, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 10 - marketscreener.com
Prime Medicine Stockholders Reaffirm Board and Auditor Choices - TipRanks
Prime Medicine (PRME) awards director David Schenkein 75,000 stock options - Stock Titan
Prime Medicine (PRME) director receives 75,000 options at $3.06 - Stock Titan
Prime Medicine (PRME) director and 10% owner receives 75,000-share option grant - Stock Titan
Prime Medicine (PRME) director receives 75,000-share stock option grant - Stock Titan
Prime Medicine (PRME) awards director 75,000 stock options at $3.06 - Stock Titan
Prime Medicine (PRME) director receives 75,000 stock options at $3.06 - Stock Titan
[Form 4] Prime Medicine, Inc. Insider Trading Activity - Stock Titan
Prime Medicine (PRME) shareholders elect Class I directors and ratify PwC as 2026 auditor - Stock Titan
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Moomoo
PRME Q1 2026 Earnings: EPS Misses Estimates as Pre-Commercial Biotech Continues R&D FocusROA Comparison - newsline.com
PRME: Directors and auditor were approved by stockholder vote, with results to be filed with the SEC - TradingView
PRME News | PRIME MEDICINE INC (NASDAQ:PRME) - ChartMill
We're Keeping An Eye On Prime Medicine's (NASDAQ:PRME) Cash Burn Rate - Yahoo Finance
Prime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue Estimates - Eastern Progress
Prime Medicine CEO to speak at Goldman Sachs Healthcare Conference on June 10, 2026 - Pluang
Prime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference - The Manila Times
Prime Medicine Inc. Gains 4.41% as Gene Editing Stock Tests Key ResistanceMax Pain Level - The Legal Advocate
PRME Q1 2026 Earnings: Wider-than-Expected Loss but Positive Stock Reaction Amid Pipeline ProgressDiluted EPS Report - newsline.com
Prime Medicine (PRME) Gains Ground as Shares Approach Key ResistanceGap Up Stocks - newsline.com
Prime Medicine to Present at Jefferies Global Healthcare Conference - The Manila Times
Prime Medicine CEO to speak at Jefferies Healthcare Conference on June 4, 2026 - Pluang
Prime Medicine (PRME) Surges Over 11% as Gene Editing Stock Finds Support Near $3.13Factor Valuation - The Legal Advocate
PRME - Finviz
Prime Medicine Inc. (PRME) Q1 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development PhaseEPS Estimate Trend - The Legal Advocate
PRME Q1 2026 Earnings: EPS Worse Than Expected as Pre-Revenue Biotech Advances PipelinePro Level Trade Signals - Newser
PRME Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Focuses on Pipeline Progress - Newser
Prime Medicine (PRME) Q1 2026 Disappoints — EPS $-0.28 Below $-0.26 ViewsEarnings Turnaround - Newser
Prime Medicine slips after Q4 updates - MSN
Finanzdaten der Prime Medicine Inc-Aktie (PRME)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):